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1. Epidemiology
   Ebola virus (EBOV) and Marburg virus (MARV), members of the 
Filoviridae virus family, are known as emerging and re-emerging 
zoonotic pathogens causing acute hemorrhagic fever with a high 
case-fatality rate in humans (up to 90%)[1].
   Ebola hemorrhagic fever (EHF) was first reported in 1976 during 
the Ebola outbreak in the Democratic Republic of the Congo 
(formerly Zaire), and the virus is named after the Ebola River where 
it was discovered. Since then, 21 additional Ebola virus disease 
(EVD) outbreaks among humans have occurred in the tropical 
regions of sub-Saharan Africa. The largest one to date took place in 
the Gulu District of Uganda in 2000-2001 caused by Sudan virus 
(SUDV). This outbreak resulted in 425 cases, of which 216 were 
laboratory confirmed, and the overall case fatality rate was 53%[2]. 
The Ebola strain that is now circulating in West Africa bears shows 
the homology of 97% with Zaire Ebola virus samples found in the 
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Democratic Republic of Congo and Gabon[2]. Historically, this strain 
has caused the highest mortality (90%), while the current estimate of 
case fatality rate is less than 60%[3].
   During December 2013, the epidemic of EVD started in Guinea[2], 
and the World Health Organization (WHO) received official 
notification of a rapidly evolving outbreak of EVD on March 23, 
2014. In August 2014, WHO declared this epidemic to be a “public 
health emergency of international concern”[3]. In mid-September 
2014, the case fatality rate among patients with definitive outcomes 
was 70.8% [95% confidence interval (CI), 68.6 to 72.8] and was 
consistent among Guinea, Liberia, and Sierra Leone. Nigeria’s case 
fatality rate was lower at 45.5%, although the current estimate is 
based on only 11 recent cases. The in-hospital case fatality rate was 
64.3% (95% CI, 61.5 to 67.0), which was lower than those for all 
patients with definitive outcomes, and this rate was consistent among 
countries. A range of 56.1% (95% CI, 41.0 to 70.1) in Guinea to 
80.0% (95% CI, 68.7 to 87.9) in Liberia of health care workers died. 
Despite multinational and multisectoral responses to the disease, 
a growing number of new cases and deaths were reported every 
week[4].
   There is no change in the control measures for this epidemic and 
by November 2, 2014, the cumulative reported numbers of Ebola 
confirmed and suspected cases for Guinea, Liberia, and Sierra 
Leone are predicted to be 5 740, 9 890, and 5 000, respectively, 
exceeding 20 000 cases in total[4]. The majority of cases are between 
15 to 44 years old (49.9% male). In terms of reported morbidity 
and mortality, the current EVD epidemic is much greater than all 
previous outbreaks combined. The real number of those who have 
been infected and died is likely much higher[4].
   This time, the outbreak has become so large that the three most-
affected countries, namely, Guinea, Liberia, and Sierra Leone, face 
numerous challenges for the implementation of rigorous control 
measures at the scale needed to prevent transmission and to supply 
all EVD patients with clinical care[4].
2. Species of ebola viruses
   The genus Ebolavirus is classified into five different viruses: 
SUDV, Tai Forest virus, Reston virus, EBOV, and Bundibugyo virus. 
Among them, EBOV causing the EHF is associated with the highest 
fatality rate in humans (57%-90%), followed by SUDV (41%-65%) 
and Bundibugyo virus (40%). To date, Tai Forest virus has only been 
known to cause two nonfatal human infections, while Reston virus 
causes asymptomatic infection in humans[5,6]. The viral hemorrhagic 
fevers (VHFs) represent a group of diverse animal and human 
diseases caused by RNA viruses belonging to four distinct families 
including Arenaviridae, Filoviridae, Bunyaviridae and Flaviviridae. 
The severity and clinical symptoms of VHFs may significantly 
change depending on different factors: the type of causative agent, 
and the epidemiological and clinical features of host. In general, all 
patients show evidences of fever and coagulation abnormalities that 
may lead to disseminated intravascular coagulation, multiple organ 
failure, signs of shock and eventually death. The VHF can be severe 
and life-threatening, and it may occur as isolated cases, such as cases 
imported from endemic areas, or may cause a devastating lethal 
outbreak. Human sporadic and outbreak cases have been reported 
with high case-fatality rates, involving social and economical 
disruption[7].
2.1. Structures
   Filoviruses are enveloped particles with a non-segmented, single-
stranded, negative-sense RNA genome, approximately 19 kb in size. 
EBOV and MARV genomes encode seven structural proteins, and also 
EBOV encodes two nonstructural soluble glycoproteins (GP): soluble 
GP and small soluble GP. All known MARV strains consist of one 
species Lake Victoria marburgvirus, while EBOV strains consist of 
four different species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus 
(SEBOV), Côte d’Ivoire ebolavirus (CIEBOV) and Reston ebolavirus 
(REBOV). The newly discovered Bundibugyo ebolavirus (BEBOV) 
has been proposed as the fifth species. The species vary in their 
apparent pathogenicity in humans; ZEBOV is the most pathogenic 
(up to 90% case fatality rate), followed by SEBOV (approximately 
50% case fatality rate) and BEBOV (approximately 40% case fatality 
rate). CIEBOV and REBOV cause lethal infections in nonhuman 
primates, but not being associated with fatal human cases yet[1,8]. 
   By systematic viral replication, EBOV and MARV result in the 
release of high levels of inflammatory cytokines, coagulation 
abnormalities and fluid distribution problems. These processes are 
observed as hemorrhage and vascular leakage; ultimately these may 
lead to multiple organ failure and shock[9,10].
   ZEBOV was first discovered in 1976, being the most virulent 
species with case fatality rates in humans up to 90% and as high 
as 100% lethality in experimental macaque models, the current 
gold standard animal model for ZEBOV among other established 
models[11].
2.2. Reservoir
   Recent evidence has confirmed the importance of bats as potential 
reservoir species of filoviruses; however, it is unclear whether other 
species are also involved or how transmission to humans and/or 
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apes takes place. EHF is believed to persist in a reservoir species 
generally found in endemic places. Apes, man, and perhaps other 
mammalian species being susceptible to Ebola virus infection are 
considered as end hosts of Ebola rather than as reservoir. Although 
wide efforts have been made to find the natural reservoirs in large 
outbreaks of EHF, neither potential hosts nor arthropod vectors have 
been identified. For a long time, rodents and bats have been regarded 
as potential reservoir species. This was proved by experimental 
studies in African plants and animals that confirmed the transmission 
of productive infection of African fruit and insectivorous bats 
with ZEBOV, though a firm link could not be achieved[9,12]. The 
inspection for potential vectors, especially among arthropods has 
been always negative, including bedbugs (Cimex hemipterus) 
captured in the beds of infected persons[13,14].
3. Transmission
   Presumably, most index cases become infected through contact 
with an infected animal. While planning defenses against biowarfare 
agents such as filoviruses, it is important to consider that respiratory 
portal of entry is the most likely route of dissemination of agents 
such as aerosols[15].
   The virus is transmitted to people as a result of direct contact 
with body fluids containing virus (vomitus, sweat, stool, urine, 
tears, breast milk, saliva and respiratory secretions) of an infected 
patient during the acute stage of disease[3]. Epidemiological studies 
have revealed that family members are at high risk of infection 
because they may come in contact with infected body fluids or may 
help to prepare the corpse of an infected person for burial. Direct 
contact with virus containing material from contaminated hands of 
caregivers to their own mouth or eyes is the most common cause. 
Caregivers who work both at home and in hospitals are at greatest 
risk for exposure. While studies have proved the spread of EBOV and 
MARV via aerosol particles under controlled laboratory conditions 
such transmission rarely appeared in humans in a hospital or 
household setting during epidemics[3].
   Further, infection can occur through sexual contact and the virus 
has been traced in semen for up to seven weeks after recovery. It 
is recommended to control and use condoms during intercourse, 
and to avoid breast feeding for at least three months after recovery 
as to prevent secondary cases. The Center for Disease Control and 
Prevention (CDC) has clearly outlined isolation procedures[3].
   The spread of infections are also the product of nosocomial or 
occupational transmission. For instance, in the first epidemics of 
Ebola, Zaire, in 1976, the usage of contaminated needles resulted in 
simultaneous outbreak among over one hundred patients. Another 
example covers spread of the virus to an entire surgical team who 
performed an exploratory laparotomy on an EBOV infected patient 
in Kikwit in 1995. In fact, health care workers coming in contact 
with affected people were mostly consisted as the first generation 
cases in previous outbreaks. The propagation of infectious diseases 
can be avoided among health care workers through early detections 
of subjects and enforcement of appropriate preventive practices. 
Historically, outbreaks have gradually burned themselves out or 
have been controlled by effective public health measures including 
isolation of sick individuals and appropriate barrier protection 
methods for care providers and funeral services. It is believed that 
transmission of viruses needs direct contact or contact with infectious 
fluid rather than a possible aerosol route of transmission[16]. 
   EBOV and MARV are regarded as re-emerging and highly 
infectious pathogens. Outbreaks have been associated with human 
sporadic cases, involve high rates of case-fatality and cause social 
and economic disruption. The substantial clinical appearance of both 
EBOV and MARV with severe hemorrhaging in most cases has also 
contributed to the high transmission rate and the fear of epidemic 
and imported cases. According to the US CDC, EBOV and MARV 
have been classified as Category A bioterrorism agents due to their 
highly infectious nature and potential use in biological weapons[17].  
4. Clinical aspects
   Before the recent epidemic in West Africa, past EVD outbreaks 
in Central Africa had been limited in size and geographic spread, 
typically affecting one to a few hundred persons, often residing in 
remote forested areas[4].
   Recognizing the signs of EVD is challenging, the incubation 
period usually lasts 5 to 7 d, although it can be as short as 2 d and 
as long as 21 d. Approximately 95% of the patients appear signs 
within 21 d after exposure which is the recommended period for 
follow-up of contacts[4]. In general, blood samples start to be tested 
positive by polymerase chain reaction-based diagnostics one day 
before symptoms onset. Typical features include fever, profound 
weakness, diarrhea, abdominal pain, cramping, nausea and vomiting 
for 3-5 d and maybe persisting for up to a week. Some patients 
may also have pharyngitis and maculopapular rash. Laboratory 
complications including elevated aminotransferase levels, marked 
lymphocytopenia, and thrombocytopenia may have occurred[2,4].
   Clinical EHF is featured by sudden onset of fever, fatigue, chills, 
general malaise, headaches, myalgia, anorexia and gastrointestinal 
distress within 3-13 d following exposure to virus. Many patients 
develop hemorrhagic manifestations from which the term 
“hemorrhagic fever” has been derived[2]. Hemorrhagic fever occurs 
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in less than half of infected subjects and gross bleeding is relatively 
rare[3]. The most common signs reported between symptom 
appearance and case detection included fever (87.1%), fatigue 
(76.4%), loss of appetite (64.5%), vomiting (67.6%), diarrhea 
(65.6%), headache (53.4%) and abdominal pain (44.3%). Certain 
hemorrhagic features were rarely reported (in <1% to 5.7% of 
patients); however, unexplained bleeding was reported in 18.0% 
of cases. These patterns are the same for all countries[4]. Bleeding 
takes place most commonly in the gastrointestinal tract and may 
demonstrate as melena, petechiae, conjunctival hemorrhage, 
hematuria, easy bruising, or intraperitoneal bleeding. Mucous 
membrane bleeding, failure of venipuncture sites and excessive clot 
formation have also been described. These symptoms progress over 
the time and patients suffer from dehydration, stupor, confusion, 
hypotension and multi-organ failure, leading to fulminant shock 
and eventually death. Fatal cases tend to develop early clinical signs 
during the infection and death often occurs between the sixth and 
sixteenth days of illness[17,18].
5. Pathogenesis and laboratory abnormalities 
   At the entry site into the body, MARV and EBOV are capable 
to infect macrophages and other cells of the phagocytic system. 
Macrophages in vitro are highly susceptible to infection and 
produce a large number of viral particles, and hence serve as a 
vehicle to deliver the virus to a variety of organ systems such as 
liver, endothelium, spleen, lymph nodes, kidney, adrenal gland, and 
pancreas[19,20].
   Marked leukopenia with a left shift and atypical lymphocytes 
can be observed on peripheral smears of infected patients. Since 
lymphocytes are not assumed to be host targets for the virus, a 
substantial reduction in the number of lymphocytes is supposed as a 
result of bystander apoptosis, showing the death of a large number of 
lymphocytes triggered by mediators which are released from virus 
infected target cells and/or secretion of viral GP. Impaired production 
of pro-inflammatory cytokines and impaired stimulation of T cells 
also play a role in this phenomenon[20].
   EBOV seems to utilize multiple cellular pathways for entry into 
host cells. Potential key mechanisms in neutralization cover direct 
inhibition of GP attachment to cell surface or endosomal receptors 
and blocking fusion of the viral and host membranes. Preventing 
cathepsin-induced cleavage is another formal possibility, albeit 
controversial. Through experimental infection of nonhuman 
primates (the gold standard animal model for Ebola virus infection), 
laboratory studies have known many aspects of the disease, because 
the signs and disease induced in these animals are very similar to 
those appeared in humans[2]. 
   Filoviruses lead to highly cytopathic effect and are capable of 
rapidly replicating to high viral doses in a wide range of cells and 
cause their lyses. Filoviruses enter via small skin lesions and mucus 
membranes from which a direct access to the vascular system is 
available. There, monocytes, macrophages and dendritic cells are 
infected in the early stage of the disease; and due to rapid spread 
of the virus through the organs, particularly in the spleen, liver, 
and lymph nodes, the spectrum of target cells increases to include 
endothelial cells, fibroblasts, hepatocytes and many other cells. 
Consequently, critically ill patients display intensive viremia and 
antigenemia[2].
   Extensive information on EHF pathophysiology have been obtained 
from the samples collected during the Gulu outbreak including the 
observation of aspartate aminotransferase, D-dimer, blood urea 
nitrogen and higher creatinine levels than normal, although calcium 
and albumin levels are less than normal in samples from fatal EHF 
cases[21]. Fatal rates were also affected by elevated levels of the 
cytokines interleukin 6, interleukin 8, interleukin 10 and macrophage 
inflammatory protein 1β. Further, human leukocyte antigen B67 
(HLA-B67), HLA-B15 and marked CD8 lymphopenia contributed 
to fatal outcome, while HLA-B7 and HLA-B14 were associated with 
nonfatal outcomes in humans[22].
6. Molecular assays
   Ebola laboratory diagnosis can be achieved in two different 
ways: measuring the host-specific immune responses to infection 
and detection of viral particles, or particle components in infected 
individuals. Nowadays, RT-PCR and antigen detection ELISA are the 
main diagnostic assays for acute infections. Viral antigen and nucleic 
acid can be traced in blood from Day 3 up to Day 7-16 following 
symptoms begin[9,23]. 
   The most general assays used for antibody detection are direct IgG 
and IgM ELISAs and IgM capture ELISA. IgM antibodies can appear 
as early as two days following the onset of signs and disappear 
between 30 and 168 d after infection. IgG-specific antibodies 
develop between 6 and 18 d after illness onset and persist for a long 
time. An IgM or rising IgG titer (four-fold) contributes to strong 
presumptive diagnosis[23].
   Considering the physiological kinetics of humoral response and 
since VHFs resulted in impaired antigen-presenting cell functions, 
antibody titers are low at least in the earlier stages of illness. 
Therefore, serology is often not the major diagnostic option in 
critical phase, but it can be a particular useful practice to confirm the 
diseases etiology in convalescent patients[24]. 
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7. Diagnosis
   For diagnosis, the best option is to have a comprehensive, 
relatively unspecific definition in accordance with both clinical 
(fever and other symptoms) and epidemiological (contact with 
a case) criteria[24]. Due to poor specificity of the symptoms, it 
is difficult to practice clinical diagnosis at the beginning of the 
epidemics. After identification of virus responsible for the outbreak, 
all suspected cases should be considered at high risk of exposure and 
the case definition and exposure risks must be included for better 
management of the epidemic[13,25].  
   Case definition of EVD includes index case: very first case 
(probable or confirmed) reported as the origin of the epidemic[25]; 
alert case: person with sudden appearance of high fever or sudden 
death or bleeding, bloody diarrhea, or bleeding in urine[25]; suspect 
case: person, dead or alive, who has (or had): (a) fever (>38.5°°C 
or 101.5°°F) with additional signs (severe headache, muscle pain, 
vomiting, diarrhea, abdominal pain, or unexplained hemorrhage) 
and (b) epidemiologic risk factors within the past 21 d before the 
start of symptoms (close contact with body fluids of a suspect or 
probable case of EVD, or direct handling of bush animals from 
disease-endemic areas)[25]; probable case: any person evaluated by a 
clinician, having symptoms compatible with EVD, or a dead person 
with an epidemiological link to a confirmed case[25]; contacts: person 
without suggestive symptom of the disease, but had unprotected 
contact with suspect or probable cases of EVD (living in the same 
house, providing care during the illness and participated in the burial 
rites). To assess the risk level is very important[25]; confirmed case: 
cases who had positive laboratory response on the detection of either 
Ebola virus antigen or Ebola IgG antibody[25]; not a case: person 
with no specific detectable antibody or antigen for Ebola[25].
8. Treatment and prevention
   A wide range of studies in vitro and several animal models have 
been developed for EBOV and MARV; however, currently neither a 
licensed vaccine nor an approved treatment is available. Scientists 
working in high containment facilities, health care workers in Africa 
and people residing in the affected areas in Africa run a risk of 
potential exposures. In the occurrence of bioterrorism acts involving 
filoviruses, the high-risk population could be quite extensive. Thus, 
as an important part of contingency plans, counter measures are 
developed[4-6].
   Passive transfer of serum collected from survivors of Junin 
virus or Lassa virus has confirmed effective provided therapies 
which are begun quickly following the infection[4-6]. However, the 
experiments of antibody passive transfer have highly failed to treat 
filovirus infections[7]. During a 1995 outbreak of EBOV in Kikwit, 
Democratic Republic of the Congo, seven of eight patients with 
symptoms and detectable EBOV antigen in their blood who received 
whole blood from convalescent EBOV patients survived[8]. The 
lethality rate (12.5%) from this treatment was significantly lower 
than the overall case fatality rate (80%) for the EBOV epidemic; 
however, it is often difficult to interpret the role of antibodies in the 
achieved protection since the patients received whole blood, not 
just antibodies, from recovering patients in the additional hospital 
care. After the 1995 epidemic, WHO produced a commercially 
available equine IgG product from horses hypervaccinated with 
EBOV for potential use in humans. Similar IgG preparations had 
been used with reported success for hamadryas baboons, in which 
this antibody protected against lethal EBOV challenge. In contrast, 
the commercially available equine IgG product did not fully protect 
cynomolgus macaques against EBOV, although clinical feature 
onset, viremia levels and time to death were delayed relative to the 
controls[26].
   Recently, a great attention has been paid to unlicensed treatments 
and vaccines. A “cocktail” of humanized-mouse antibodies (ZMapp) 
is among the therapies in development, showing promise in 
nonhuman primates. Two US citizens who recently evacuated from 
Liberia to Atlanta were given ZMapp and both patients demonstrated 
clinical improvements. Other candidate therapeutics cover RNA-
polymerase inhibitors and small interfering RNA nano particles 
that are inhibitors of protein production. The results obtained from 
gene-silencing treatment using small interfering RNAs have been 
good both in guinea pigs and non-human primate models of Ebola 
infections. This data suggests that RNA interference may be an 
effective post-exposure treatment strategy for people infected with 
Ebola virus and perhaps other VHF agents. Unfortunately, production 
and cost issues can substantially constraint the current use of this 
approach[24]. 
   Preclinical evaluation is also underway for various vaccine 
candidates. One is a chimpanzee adenovirus vector vaccine, into 
which two Ebola genes encoding glycoproteins have been inserted. 
Two other vaccine candidates involve vesicular stomatitis virus 
pseudotypes. Human clinical trials for one of these vaccines is 
planned to start in early 2015[3].
   In the past decade, many efforts have been made in the 
development of different vaccine platforms and treatment strategies 
against filoviruses. Though there is a lack of highly efficacious 
treatment options, multiple vaccine platforms have been developed 
with good efficacy against EBOV and MARV including virus-like-
particles, Venezuelan equine encephalitis virus replicons, replication 
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incompetent adenovirus serotype 5 vectors, replication competent 
recombinant human parainfluenza virus 3 and recombinant vesicular 
stomatitis virus (rVSV). All these platforms have been assessed in the 
nonhuman primate models and proved to be protective. Currently, 
the rVSV platform is one of the more promising vaccine approaches 
against filoviruses. As a nonsegmented, negative stranded RNA virus 
in the family Rhabdoviridae, VSV is primarily an animal pathogen, 
and no evidence is available for its role for acute illness in humans. 
Two serotypes, designated as serotypes New Jersey and Indiana, 
are known to be circulating on the American continent. Both are 
transmitted via mosquitoes, sand flies or black flies and cause a 
deadly effect. Two rVSV vaccine vectors have been extensively 
investigated over filovirus animal disease models: rVSV/ZEBOV-
GP expressing the GP derived from ZEBOV strain Mayinga and 
rVSV/MARV-GP expressing the GP derived from MARV strain 
Musoke[10,16]. 
   The efficacy of rVSV/ZEBOV-GP in vaccine or post-exposure 
treatments has been tested through mouse-adapted ZEBOV in mice 
and hamsters, guinea pig-adapted ZEBOV in guinea pigs and ZEBOV, 
SEBOV, CIEBOV and BEBOV in nonhuman primates. The researchers 
showed protective efficacy data of rVSV/MARV-GP against MARV 
infection[14]. The protection for post-exposure rVSV treatment is 
still an unknown mechanism. Acting as a vaccine vector to induce 
very strong immune responses, VSV can overcome filovirus-driven 
suppression of these responses, thus inhibiting filovirus replication 
and infection spread. It has been revealed that rVSVs infect the 
same target cells as filoviruses and the viral interference leads to a 
block in EBOV and MARV replication. Again, the development of a 
humoral non neutralizing immune response contributed in survival, 
but this is unlikely to be a protective mechanism due to its late 
development[27,28]. 
   At least, six different vaccine systems are promising complete 
protection for nonhuman primates against MARV or EBOV infection 
among those prospective vaccines with efficacy in nonhuman 
primate models of filoviral hemorrhagic fever; two options, one 
based on a replication-defective adenovirus serotype 5 and the other 
on rVSV, have shown complete protection to nonhuman primates 
when administered as a single injection[5]. 
   There are no approved vaccines or antiviral therapeutics for MARV 
or EBOV currently available for human use. Although MARV or 
EBOV hemorrhagic fevers are rare diseases, vaccination could be an 
important preventive tool for several groups including risk groups 
during filovirus epidemics in affected regions in sub-Saharan Africa 
(medical personnel, patient care personnel, family members); 
national and international healthcare workers and outbreak response 
personnel; laboratory workers conducting research on filoviruses; 
military and other service personnel susceptible to filoviruses used 
as bio weapons[5,29].
   VSV is the prototypic member of the family Rhabdoviridae and 
a number of its certain characteristics are important for a vaccine 
vector, namely, replication in almost all known mammalian cell 
lines, growth to very high titers and a strong induction of innate and 
adaptive (humoral as well as cellular) immune responses[1,30].
   Providing vaccines to people before traveling to endemic regions 
of the world could help prevent life-threatening diseases. An 
effective preventive vaccine has the potential to defend against 
regional epidemics and reduce the likelihood of global transmission 
of filovirus infections. Studies on rhesus macaques prove that 
treatment with recombinant inhibitor of factor VIIa/tissue factor and 
activated protein C contributed to significant increased survival after 
the experimental infection with ZEBOV[31].
   Activated protein C, recombinant inhibitor of factor VIIa/tissue 
factor and modipafant might be considered in future clinical 
experimental plans for severe dengue and/or Ebola infections 
in patients which are known to proceed through shock and not 
responsive to standard support treatments. Finally, it was found that 
transgenic mice expressing very high levels of human mannose-
binding lectin concentrations (a C-type lectin that recognizes hexose 
sugars and acts as a first-line host defense against a wide range of 
viral pathogens) are more resistant to fatal Ebola infections than 
wild-type mice[32]. This suggests that modulation of mannose-
binding lectin activity may be an interesting field for further clinical 
studies[24]. 
   Ebola patients receive supportive care; no licensed therapy is 
known to be effective against the virus. Basic clinical supports 
consist of aggressive volume and electrolyte management, oral and 
intravenous nutritional therapy and medical interventions to control 
fever and gastrointestinal distress as well as to treat pain, anxiety and 
agitation. Diagnosis and treatment of concomitant infections and 
super infections including malaria and typhoid are also regarded as 
important aspects of patient care[24]. 
   In the recent past, experimental post-exposure interventions 
against filovirus infections have consisted of hyperimmune equine 
IgG, EBOV-specific human monoclonal IgG antibody, whole blood 
transfusions from convalescent survivors, recombinant interferon, 
recombinant nematode anticoagulant protein C2, recombinant 
human activated protein C, rVSV vectors, small interfering RNAs and 
phosphorodiamidate morpholino oligomers[26].
   These interventions can reduce the likelihood of early infections in 
humans; improve biological safety; provide infection-control training 
and equipments for hospitals and ambulances; decrease the number 
of epidemics; provide leadership for behavioral change involving 
Saeed Reza Jamali Moghadam et al./Asian Pac J Trop Biomed 2015; 5(4): 260-267266
safe burial practices and equipments; communicate with community 
members and health workers; reduce the spillover of zoonotic 
diseases into human populations; prevent contact between humans 
and bats; improve food security; and minimize dangerous handling 
of consuming bush meat. Three core treatments have contained all 
previous outbreaks of various Ebola viruses and can stop this one 
as well: exhaustive case and contact finding, effective response to 
patients and the community and preventive interventions[27].
   Laboratory experiment with RT-PCR provides sensitivity and 
specificity and can return the results within some hours; the test is 
now becoming more popular and widely available in the affected 
areas. Responding to cases includes the treatment of patients while 
isolated, through contact tracing and monitoring all contact up 
to 21 d after exposure. It is difficult to isolate and treat people 
with EVD, not because the illness is particularly infectious or it is 
particularly hardy virus, but a single lapse can have devastating 
consequences.
   Neither negative air flow nor special respirators are needed; 
it requires meticulous and scrupulous attention to guidance on 
gown, gloves, facemask and eye protection and great caution while 
removing protective equipments. Improvements in hospital infection 
control measures throughout the region would have a significant 
impact on the number of EVD and other diseases. Soap and water 
or alcohol-based hand sanitizers can disrupt the envelope of this 
single-stranded RNA virus, and dilute bleach effectively protects 
against contamination and are readily available even in remote 
settings. Provision of supportive therapy especially fluid and 
electrolyte maintenance and treatment of bacterial super-infections 
can substantially improve survival rate. Initiating identification 
of contacts and measure of people’s temperature daily for 21 d 
following exposure are needed[33].
   There are three main prevention interventions, and the first is to 
practice strict infection control measures in health care settings; the 
highest risk of transmission occurs among patients with delayed 
detection and isolation, not those with diagnosed infection. The 
second is to provide education and support for the community 
regarding modification of long-standing burial traditions aimed for 
preventing direct contact with the blood and body fluids of infectious 
people, at least temporarily, until the outbreak is controlled; and 
it will stop the second key medium of the virus widespread. This 
issue is culturally sensitive that requires culturally relevant and 
appropriate outreach and educational materials. The third is to avoid 
direct contacts with bush meat (wild animals hunted for sustenance) 
and bats (that may be the primary natural hosts of Ebola virus) 
can eliminate the risk of early importation of Ebola virus into 
humans[33].
   Health-care workers’ knowledge and practices regarding the safe 
infection-control measures including an appropriate use of personal 
protective equipment offer protection to both workers and patients, 
because health care associated infection has been a major cause of 
transmission during previous outbreaks[27,33,34].
   Suspected patients should be isolated immediately from other 
patients and barrier practices should be instituted. In addition, strict 
precautions should be taken when dealing with specimens to avoid 
propagation of the infection among caregivers. Precaution tools need 
to be consistently used, like gloves, gowns, face shields, masks and 
eyewear. Further, the existing CDC guidelines recommend respiratory 
protection by using N-95 respirators. Cleaning and decontaminating 
surfaces and objects contacting with patients must be considered in 
order to prevent the transmission to health care workers and family 
members[27].
9. Conclusions
   EVD is a painful reminder that an outbreak anywhere can be 
a risk everywhere. The Global Health Security Agenda seeks to 
enforce public health systems in most affected countries in order to 
eliminate the spreads before they become emergencies. Although 
great improvements have been achieved over the past decade, better 
surveillance, real-time sharing of data and taking rapid action based 
on the available information remain necessary. Because Ebola virus 
is primarily transmitted through contact with the body fluids of 
symptomatic patients, the infection spread can be stopped by an 
early diagnosis, contact tracing, patient isolation and care, infection 
control and safe burial.
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